CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
CURRENT ASSETS
Cash and cash equivalents	$ 132,211	$ 89,132
Research supplies	54,530	57,785
Grant funds receivable	20,000	38,000
Prepaid expenses and other current assets	52,237	64,543
Total current assets	259,358	249,022
PROPERTY AND EQUIPMENT, NET	3,703	4,929
Total assets	263,061	253,951
CURRENT LIABILITIES
Accounts payable and accrued liabilities	81,375	127,217
Total current liabilities	81,375	127,217
LONG TERM LIABILITIES
Accrued licensing fees	622,000	652,000
Other liabilities	138,645	145,396
Total long term liabilities	760,911	797,755
Total liabilities	842,286	924,972
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' DEFICIT
Common stock, par value $0.001 per share; 300,000,000 shares authorized; 24,879,350 and 24,379,350 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively	24,880	24,380
Additional paid-in capital	9,363,404	9,144,464
Accumulated other comprehensive loss	(35,720)	(31,231)
Accumulated deficit	(9,932,773)	(9,812,564)
Total Proteo, Inc. Stockholders' Deficit	(579,225)	(674,127)
Noncontrolling Interest	0	3,106
Total stockholders' deficit	(579,225)	(671,021)
Total liabilities and stockholders' deficit	263,061	253,951
Series A Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Preferred stock value	724	724
Series B-1 Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Preferred stock value	100	100
Series B-2 Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Preferred stock value	$ 160	$ 0